Sugi Predict

Sugi Predict / Compounds / SCHEMBL1521610

SCHEMBL1521610

SCHEMBL1521610

CCN1C(=O)N(c2ccc(F)c(NC(=O)Nc3cc(C(C)C)no3)c2)Cc2cnc(NC)nc21

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 2/20 0.39
▸ RAF1 P04049 2/20 0.39
▸ BRAF P15056 2/20 0.39
▸ KDR P35968 2/20 0.39
▸ MAP2K2 P36507 2/20 0.39
▸ MAP2K1 Q02750 2/20 0.39
▸ FGFR4 P22455 11/20 0.38
▸ TNK2 Q07912 1/20 0.36
▸ MAP4K2 Q12851 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ FGFR1 P11362 5/20 0.35
▸ FGFR2 P21802 4/20 0.35
▸ FGFR3 P22607 4/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NEK7 Q8TDX7 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521670 0.89 BRAF (0.51) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1521751 0.88 TNK2 (0.42) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1521861 0.87 MAPK14 (0.39) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1521624 0.86 BRAF (0.44) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1896027 0.86 EGFR (0.43) FGFR4MAPK14EGFR
SCHEMBL1522039 0.83 FGFR4 (0.44) KRASRAF1BRAFKDRFGFR4
SCHEMBL1522047 0.82 BRAF (0.46) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1521792 0.81 FGFR4 (0.39) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1521793 0.80 BRAF (0.48) KRASRAF1BRAFKDRMAP2K2
SCHEMBL1521552 0.80 BRAF (0.46) KRASRAF1BRAFKDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 — — US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 — — US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 KRAS 30/4885RAF1 3/4885BRAF 1/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 KRAS 30/4885RAF1 3/4885BRAF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.